

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/074182 A9

(51) International Patent Classification:
C12N 15/63 (2006.01)

(21) International Application Number:
PCT/EP2021/077820

(22) International Filing Date:
08 October 2021 (08.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20201096.3 09 October 2020 (09.10.2020) EP

(71) Applicants: STADA ARZNEIMITTEL AG [DE/DE];
Stadastraße 2-18, 61118 Bad Vilbel (DE). XBRANE
BIOPHARMA AB [SE/SE]; Banvaktsvägen 22, 171 48
Solna (SE).

(72) Inventors: VIKSTRÖM, David; Vallmovägen 2, 194 68
Upplands Väsby (SE). ISMAIL, Nurzian; Swedenborgs-
gatan 26, 118 27 Stockholm (SE). SAMUELSON, Patrik;
Älgövägen 21, 133 36 Saltsjöbaden (SE). MIRZADEH,
Kiavash; Storgatan 70C, 171 52 Solna (SE). GUDISE,
Santhosh; Terapivägen 12 A, 141 56 Huddinge (SE). KAD-
OW, Maria; Lantgårdsvägen 105, 192 74 Sollentuna (SE).
SZEKÉR, Kathleen; Finnvidsvägen 13, 182 33 Danderyd
(SE). SALIH, Tagrid; Bällstavägen 203, 168 57 Brom-
ma Kyrka (SE). BARASZKIEWICZ, Mariusz; Björk-
backsvägen 42, 168 69 Bromma (SE). BASHIRI, Siavash;
Sjöviksbacken 5, 117 57 Stockholm (SE).

(74) Agent: MAIWALD PATENTANWALTS- UND
RECHTSANWALTSGESELLSCHAFT MBH; Kerstin
Wolff, Elisenhof, Elisenstr. 3, 80335 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the revised international search
report:

16 June 2022 (16.06.2022)

(15) Information about Correction:

see Notice of 16 June 2022 (16.06.2022)

(54) Title: METHOD OF PRODUCING A RECOMBINANT PROTEIN IN A HOST CELL WHICH HAS A DISABLED RHAM-
NOSE METABOLISM AS WELL AS EXPRESSION VECTORS, HOST CELLS AND RECOMBINANT PROTEINS THEREOF

(57) Abstract: The present invention relates to DNA construct suitable for expressing a recombinant protein in a bacterial host cell wherein said DNA construct comprises nucleotide sequences encoding: a *rhaBAD* promoter, a RhaR transcription activator, a RhaS transcription activator, an antibiotic resistance marker, a promoter operably linked to the nucleic acid encoding for the antibiotic resistance marker, an mB T1 terminator, an mB T2 terminator and a pMB1 origin of replication. The DNA construct may also comprise a nucleotide sequence encoding said recombinant protein operably linked to the *rhaBAD* promoter. The present invention further relates to a vector and bacterial host cell comprising said DNA construct as well as a method of producing said recombinant protein by exposing said bacterial host cell to rhamnose and thereby inducing expression of said recombinant protein.



WO 2022/074182 A9